Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Lancman

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Expert Review of Hematology|November 25, 2016
Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?Guido Lancman, John Mascarenhas
Annals of Hematology|September 22, 2021
Impact of rituximab on COVID-19 outcomesHannah Levavi, Guido Lancman, Janice Gabrilove
Hematology/Oncology and Stem Cell Therapy|July 22, 2018
Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case seriesGuido Lancman, Alexander Coltoff, Amir Steinberg
Hematology. American Society of Hematology. Education Program|December 4, 2020
Bispecifics, trispecifics, and other novel immune treatments in myelomaGuido Lancman, Joshua Richter, Ajai Chari
International Journal of Hematology-Oncology and Stem Cell Research|June 29, 2018
Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCLGuido Lancman, Amir Steinberg, Janice Gabrilove
Targeted Oncology|October 19, 2020
Targeting Nuclear Export Proteins in Multiple Myeloma TherapyNicholas Theodoropoulos, Guido Lancman, Ajai Chari
Blood Cancer Journal|September 12, 2024
Bispecific antibodies in the treatment of multiple myelomaAnup Joseph Devasia, Ajai Chari, Guido Lancman
Journal of Hematology & Oncology|October 3, 2020
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemiaGuido Lancman, John Mascarenhas, Michal Bar-Natan
Cancer Research|October 2, 2023
A Landmark Paper That Introduced Proteasome Inhibition in MyelomaAnup Joseph Devasia, Guido Lancman, A Keith Stewart
Seizure|May 10, 2014
Nonconvulsive status epilepticus in patients with brain tumorsLara V Marcuse, Guido Lancman, Alexis Demopoulos, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Expert Review of Hematology|November 25, 2016
Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?Guido Lancman, John Mascarenhas
Annals of Hematology|September 22, 2021
Impact of rituximab on COVID-19 outcomesHannah Levavi, Guido Lancman, Janice Gabrilove
Hematology/Oncology and Stem Cell Therapy|July 22, 2018
Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case seriesGuido Lancman, Alexander Coltoff, Amir Steinberg
Hematology. American Society of Hematology. Education Program|December 4, 2020
Bispecifics, trispecifics, and other novel immune treatments in myelomaGuido Lancman, Joshua Richter, Ajai Chari
International Journal of Hematology-Oncology and Stem Cell Research|June 29, 2018
Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCLGuido Lancman, Amir Steinberg, Janice Gabrilove
Targeted Oncology|October 19, 2020
Targeting Nuclear Export Proteins in Multiple Myeloma TherapyNicholas Theodoropoulos, Guido Lancman, Ajai Chari
Blood Cancer Journal|September 12, 2024
Bispecific antibodies in the treatment of multiple myelomaAnup Joseph Devasia, Ajai Chari, Guido Lancman
Journal of Hematology & Oncology|October 3, 2020
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemiaGuido Lancman, John Mascarenhas, Michal Bar-Natan
Cancer Research|October 2, 2023
A Landmark Paper That Introduced Proteasome Inhibition in MyelomaAnup Joseph Devasia, Guido Lancman, A Keith Stewart
Seizure|May 10, 2014
Nonconvulsive status epilepticus in patients with brain tumorsLara V Marcuse, Guido Lancman, Alexis Demopoulos, et al.
Pageof 4